News

Platinum-Doublet Chemo Shows Efficacy as a Second-Line Treatment for Relapsed SCLC

05/06/2021

For patients with relapsed SCLC, second-line, platinum-doublet chemotherapy may be beneficial over non-platinum regimens.

For patients with relapsed SCLC,...

05/06/2021

Oncology

News

PD-L1 Inhibitor Plus Etoposide-Platinum Regimen Promising for Extensive-Stage SCLC

11/11/2020

Results from a systematic review show that a PD-L1 inhibitor plus etoposide-based chemotherapy could be an optimal first-line treatment for ES-SCLC.

Results from a systematic review...

11/11/2020

Oncology

News

Basics of Immunotherapy in SCLC

10/03/2020

In a session presented at the 2020 Personalized Therapies in Thoracic Oncology virtual meeting, Stephen V. Liu, MD, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C, shared insight on immunotherapy treatment for SCLC.

In a session presented at the...

10/03/2020

Oncology

News

No Survival Advantage With Whole-Brain RT vs Stereotactic Radiosurgery for SCLC

08/24/2020

In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.

In patients with SCLC,...

08/24/2020

Oncology

News

First-Line Pembrolizumab Combo Improves PFS in Patients With Extensive-Stage SCLC

06/22/2020

First-line therapy with pembrolizumab plus etoposide and platinum (EP) led to significantly improved PFS compared with placebo plus EP in patients with ES-SCLC.

First-line therapy with...

06/22/2020

Oncology

News

FDA Approves Lurbinectedin for Adults With Metastatic SCLC

06/15/2020

The FDA has approved lurbinectedin for the treatment of adults with metastatic SCLC that progressed during or after platinum-based chemotherapy.

The FDA has approved...

06/15/2020

Oncology

News

Second-Line Lurbinectedin Shows Activity, Acceptable Safety in SCLC

05/12/2020

In a phase 2 study of patients with SCLC, second-line lurbinectedin was active and yielded a manageable safety profile.

In a phase 2 study of patients...

05/12/2020

Oncology

News

FDA Approves Durvalumab–Chemo Combo for Extensive-Stage SCLC

03/30/2020

The FDA has approved durvalumab plus etoposide and carboplatin or cisplatin for the first-line treatment of patients with extensive-stage SCLC.

The FDA has approved durvalumab...

03/30/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology